Research is a pillar of intensive care medicine.  It is essential to inform us how we best treat patients who are critically ill.  Conducting research in the ICU requires a careful and considered approach to the unique aspects of this environment. Our patients are often unconscious, with acute diseases that put them at high risk of dying. Their families are particularly stressed, and dealing with their own uncertainty while trying to advocate and support their loved one.

Clinical trials currently underway at the Barwon Health ICU are investigating:

  • Respiratory support after cardiac surgery
  • Medications to prevent bone loss and fractures in the years after critical illness
  • Choice of antibiotics and steroids for treating pneumonia
  • Medication to prevent gastric ulcers during critical illness
  • Mobilising critically ill patients early in their treatment
  • Protein concentration of nutrition
  • Optimal blood oxygen levels to target
  • Shared decision-making for patients with life limiting illness
  • Effective management of extracorporeal life support

Barwon Health ICU is a member of the Australian and New Zealand Intensive Care Society – Clinical Trials Group (ANZICS-CTG), and also conducts research that ranges from multi-centre clinical trials to observational studies, single site and healthcare registry studies.

Please reach out to the ICU research team if interested in collaborating, or for any further information.


Research Areas

The Barwon Health Intensive care is an international leader in research examining bone loss after critical illness. A/Prof Neil Orford is the Chief Investigator for the multicentre, MRFF funded ($1,905,282.70) BONE ZONE Trial. This trial is examining the effect of zoledronic acid or denosumab in critically ill women and men. https://www.monash.edu/medicine/sphpm/anzicrc/research/bone-zone

Outcomes of patients admitted to intensive care with haematological malignancies in an Australian tertiary hospital; a retrospective 10 year audit. This ongoing audit has identified that the outcomes of this group of patients is similar to internationally published data.

What is not known or understood is the experience of critical illness for this group of patients. As part of a higher degree qualification Allison plans to explore this area by undertaking a qualitative research project to explore this phenomena from the viewpoint of patients, their families and the ICU healthcare professionals.

It is hoped that this will inform the development of further research focussing on patient experience, person centred care and shared decision making.

  • Randomised embedded, multifactorial adaptive platform trial for community-acquired pneumonia (REMAP-CAP)
  • A comprehensive national registry on the treatment and outcomes of patients requiring ECMO (EXCEL)
  • Blend to Limit oxygen in ECMO: a randomised controlled registry trial (BLENDER)
  • Bone loss prevention with Zoledronic Acid or Denosumab in critically ill women (BONE-ZONE)
  • Re-evaluating the inhibition of stress erosions and prophylaxis against gastrointestinal bleeding in the critically ill (REVISE)
  • The effect of augmented administration of enteral protein to crucially ill adults on clinical outcomes (TARGET Protein)
  • Treatment of invasively ventilated adults with early activity and mobilisation (TEAM)
  • Targeted therapeutic mild hypercapnia after resuscitated cardiac arrest: A phase III multi‐centre randomised controlled trial (TAME) https://www.nejm.org/doi/full/10.1056/NEJMoa2214552
  • Liberal Glucose Control in Critically Ill Patients with pre-existing type 2 diabetes (LUCID)
  • Continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients (BLING-III)
  • ANZICS Point Prevalence Program (PPP)
  • 20% Human albumin solution fluid bolus administration therapy in patients after cardiac surgery (HAS FLAIR)
  • The mega randomised registry trial comparing conservative vs liberal oxygen targets (Mega-ROX)
  • Short period incidence study of severe acute respiratory infection (SPRINT-SARI)
  • Effect of denosumab on bone turnover markers in critically ill women (SOFTER)
  • International point prevalence study of intensive care unit transfusion practices status (INPUT)
  • Extracorporeal membrane oxygenation for 2019 novel coronavirus acute respiratory disease (ECMO CARD)
  • Intensive nutrition therapy compared to usual care in critically ill adults (INTENT)

  • Identifying values, listening and advising high-risk patients in acute care (i-Validate)
  • The epidemiology and outcomes of patients admitted to the Intensive Care Unit with an acute mental health disorder
  • Factors associated with long-term survival after critical illness
  • Defining patient-centred recovery after critical illness – a qualitative study
  • Neuro-prognostication in Hypoxic Ischaemic Encephalopathy
  • Frailty and Intensive Care outcome

Mortality rates of patients managed in an intensive care unit (ICU) have been decreasing, and now 90% of patients survive to leave hospital.  While this is encouraging, we know relatively little about the health status of survivors of critical illness and their experience of ICU.  Some research has investigated long-term outcomes of critically ill patients, but this has included only a small proportion of patients managed in ICU.  We are planning to systematically determine the extent of patient recovery and obtain feedback from all survivors of critical illness.  This will provide important insight into long-term outcomes, and help us understand what clinical services ICU patients may require.



Research Team

Research staff

  • Michelle Horton, ICU Research Nurse
  • Jemma Trickey, ICU Research Nurse
  • Erfana Thashneem, Deputy Head of Research
  • Neil Orford, Head of ICU Research

Research Grants

  • 2023: AI Orford MRFF MNHS Grant: Generating new evidence to reduce complications and improve the safety and efficacy of extracorporeal membrane oxygenation (ECMO) in patients with severe cardiac and respiratory failure: THE RECOMMEND Platform Trial. $2,985,992.73.
  • 2023: CI Orford MRFF: iCare – An interactive online portal to improve health and wellbeing for people living with complex cancers, and their informal carers: a Phase II randomised controlled trial. $826,731.86
  • 2020: CIA Orford MRFF RCRDUN Grant APP1199726: Bone loss prevention with zoledronic acid or denosumab in critically ill women – A randomised controlled trial. $1,905,282.70

Eastwood G, Nichol AD, Hodgson C, et al for the TAME Study Investigators. Mild Hypercapnia or Normocapnia after Out-of-Hospital Cardiac Arrest. N Engl J Med. 2023 Jul 6;389(1):45-57. doi: 10.1056/NEJMoa2214552. https://www.nejm.org/doi/full/10.1056/NEJMoa2214552
Hodgson CL, Higgins AM, Bailey MJ…Orford N, for the EXCEL Study Investigators on behalf of the International ECMO Network and the ANZICS CTG. Incidence of death or disability at 6 months after extracorporeal membrane oxygenation in Australia: a prospective, multicentre, registry-embedded cohort study. Lancet Respir Med. 2022 Nov;10(11):1038-1048. doi: 10.1016/S2213-2600(22)00248-X. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00248-X/fulltext
Milnes S, Hutchinson A, Kerr D…Orford N. Effect of communication skills training on documentation of shared decision-making for patients with life-limiting illness: an observational study in an intensive care unit.Crit Care and Resusc. 2023. Mar (25)1:20-26 https://www.sciencedirect.com/science/article/pii/S1441277223000054
Thackeray M, Kotowicz MA, Pasco JA, Mohebbi M, Orford N. Changes in body composition in the year following critical illness: A case-control study. J Crit Care. 2022 Apr 23;71:154043. https://www.sciencedirect.com/science/article/abs/pii/S0883944122000727
 Low Y, Lyon C, Lakey K, Finnis ME, Orford NR, Maiden MJ. Frailty is not independently associated with intensive care unit length of stay: An observational study. Aust Crit Care. 2021 Aug 27:S1036-7314(21)00106-5. doi: 10.1016/j.aucc.2021.06.012. https://www.sciencedirect.com/science/article/abs/pii/S1036731421001065
 Orford N. Grief After Suicide. 2020; 323(17):1720-1721. https://jamanetwork.com/journals/jama/article-abstract/2765432#:~:text=We%20can%20share%20sorrow%2C%20sit,piece%20together%20events%20and%20emotions.

Support Our Research

Participate in a Clinical Trial

To find out about clinical trials currently underway at Barwon Health, click here.

Donate

Clinical trials require ongoing investment and there are several ways to support this amazing work.

You can make a donation today and contribute to an item on our research wish list, consider a bequest in your will, or establish a lasting legacy fund in your name. No matter what size, your philanthropic support with deliver an immediate impact.

To donate now or for more information and further discuss your support, please contact the Barwon Health Foundation.

Wish  List

  1. $2,000 will fund the purchase of IT software for data analysis and data presentation
  2. $5,000 will fund a -80 degrees freezer for storing biological samples
  3. $50,000 will fund the Project Coordinator who is essential to conducting of a planned Patient Related Outcomes Study.

Page last updated: July 22, 2024